BioLine Rx (FRA:YP2) Cyclically Adjusted FCF per Share: €-63.29 (As of Mar. 2026)


FRA:YP2 BioLine Rx Ltd FRA:YP2
21 GF Score
Price €2.52
! 5 Warning Signs
View Full Analysis

What is BioLine Rx Cyclically Adjusted FCF per Share?

BioLine Rx FRA:YP2 21 Cyclically Adjusted FCF per Share is €-63.29 as of Mar. 2026. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BioLine Rx's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.446. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-63.29 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 22.10% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BioLine Rx was 24.90% per year. The lowest was 5.30% per year. And the median was 22.20% per year.

As of today (2026-07-09), BioLine Rx's current stock price is €2.52. BioLine Rx's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-63.29. BioLine Rx's Cyclically Adjusted Price-to-FCF of today is .


BioLine Rx  (FRA:YP2) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BioLine Rx Cyclically Adjusted FCF per Share Related Terms


BioLine Rx Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BioLine Rx's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx Cyclically Adjusted FCF per Share Chart

BioLine Rx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -238.67 -160.46 -112.71 -61.76 -71.08

BioLine Rx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -92.54 0.00 -68.09 -71.08 -63.29

FRA:YP2 vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, BioLine Rx's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Cyclically Adjusted Price-to-FCF falls into.


FRA:YP2
21GF Score
BioLine Rx Ltd FRA:YP2
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioLine Rx's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.446/330.2130*330.2130
=-0.446

Current CPI (Mar. 2026) = 330.2130.

BioLine Rx Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -31.266 241.018 -42.837
201609 -28.266 241.428 -38.661
201612 -39.442 241.432 -53.946
201703 -72.082 243.801 -97.630
201706 -24.159 244.955 -32.568
201709 -30.776 246.819 -41.174
201712 -32.695 246.524 -43.794
201803 -31.565 249.554 -41.767
201806 -30.118 251.989 -39.467
201809 -28.793 252.439 -37.664
201812 -70.884 251.233 -93.168
201903 -18.545 254.202 -24.090
201906 -23.649 256.143 -30.488
201909 -22.589 256.759 -29.051
201912 -18.646 256.974 -23.960
202003 -20.741 258.115 -26.534
202006 -13.466 257.797 -17.249
202009 -9.403 260.280 -11.929
202012 -8.440 260.474 -10.700
202103 -5.625 264.877 -7.012
202106 -5.097 271.696 -6.195
202109 -3.605 274.310 -4.340
202112 -4.149 278.802 -4.914
202203 -4.268 287.504 -4.902
202206 -5.026 296.311 -5.601
202209 -7.121 296.808 -7.922
202212 -3.621 296.797 -4.029
202303 -4.946 301.836 -5.411
202306 -5.884 305.109 -6.368
202309 -6.009 307.789 -6.447
202312 2.538 306.746 2.732
202403 -7.183 312.332 -7.594
202406 -5.286 314.175 -5.556
202409 -4.428 315.301 -4.637
202412 -3.770 315.605 -3.944
202503 -0.649 319.799 -0.670
202506 -0.039 322.561 -0.040
202509 -0.413 324.800 -0.420
202512 -0.616 324.054 -0.628
202603 -0.446 330.213 -0.446

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-63.29 mean?
BioLine Rx (FRA:YP2) has a Cyclically Adjusted FCF per Share of €-63.29 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioLine Rx and its competitors.
Is BioLine Rx's Cyclically Adjusted FCF per Share too high?
BioLine Rx's current Cyclically Adjusted FCF per Share is €-63.29. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
BioLine Rx's Cyclically Adjusted FCF per Share of €-63.29 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioLine Rx and its competitors. BioLine Rx's current Cyclically Adjusted FCF per Share is €-63.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (FRA:YP2) has a current Cyclically Adjusted FCF per Share of €-63.29. The current Cyclically Adjusted FCF per Share is €-63.29. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current Cyclically Adjusted FCF per Share is €-63.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Other Exchanges BLRX:USABLRX:Israel
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score

Get the complete analysis for FRA:YP2

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price